Login to Your Account

Financings Roundup

Milestone Garners $13M Equity Financing for PSVT Heart Drug

By Catherine Shaffer

Tuesday, June 14, 2011
Canadian biotech Milestone Pharmaceuticals Inc. took home C$13 million (US$13.3 million) in an equity financing round to boost development of its cardiovascular candidate, MSP-2017. The drug offers hope of a short-acting, as-needed treatment for episodes of paroxysmal supraventricular tachycardia (PSVT) that may allow patients to discontinue chronic therapy and stay out of the emergency room.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription